N@N

Positron Exhibits at the Society of Nuclear Medicine Meeting to Promote Their Cardiac Optimized PET Scanner

^{Published on 2010-06-01 19:04:26 - Market Wire}
 

INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC) a molecular imaging solutions company focused on Nuclear Cardiology, will exhibit at the upcoming Society of Nuclear Medicine Meeting (SNM) in Salt Lake City, UT June 5^th-9^th to promote their cardiac optimized PET scanner, the Attriusa" ([ www.snm.org ]).

"The Attriusa" has a small footprint, robust standard cardiovascular software package, competitive scan times and an affordable cost of entry making the Attriusa" the right choice for enhancing the capabilities of a Cardiovascular practices."

The SNM Annual Meeting has been recognized by thousands of professional attendees as the premier event for educational and networking opportunities in molecular imaging and nuclear medicine. Positron will utilize the SNM annual conference as a platform to educate its attendees about the benefits of cardiac PET and promote the Attriusa".

With the continued uncertainty of the worlds Molybdenum supply and recent increase in PET reimbursement & decrease in SPECT reimbursement, cardiac PET has seen a significant rise in demand as doctors and hospitals look toward modalities that offer better medicine to their patients while decreasing operational costs. Joseph Oliverio, Chief Technology Officer states, aThe demand for Cardiovascular PET imaging is rapidly increasing as it enables the physician to provide better patient care through a more accurate diagnosis, the potential to reduce unnecessary downstream procedures and limit radiation exposure.a Mr. Oliverio also went on to state, aThe Attriusa" has a small footprint, robust standard cardiovascular software package, competitive scan times and an affordable cost of entry making the Attrius^a" the right choice for enhancing the capabilities of a Cardiovascular practices.a

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attriusa", a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. More information about Positron is available at [ www.positron.com ].

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317)576-0183.